Company Encyclopedia
View More
name
Bionano Genomics
BNGO.US
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics.
770.89 B
BNGO.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking57/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-78.22%E
    • Profit Margin-134.36%E
    • Gross Margin45.74%B
  • Growth ScoreD
    • Revenue YoY-13.84%E
    • Net Profit YoY71.58%A
    • Total Assets YoY-9.50%E
    • Net Assets YoY1.91%C
  • Cash ScoreD
    • Cash Flow Margin-74.43%D
    • OCF YoY-13.84%E
  • Operating ScoreD
    • Turnover0.35D
  • Debt ScoreB
    • Gearing Ratio37.01%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BioNano Genomics: Strong Market Performance and Strategic Shift Drive Buy Rating

    BioNano Genomics received a Buy rating from Maxim Group's analyst Jason McCarthy, with an $8.00 price target. The company reported strong third-quarter revenue and shifted its strategy towards higher-margin consumables and software, improving margins and reducing expenses. Adoption of Optical Genome Mapping technology is increasing, supported by new publications and CPT code approvals. Despite a 59.36% stock price drop over six months, the company's solid cash position and strategic focus support a positive outlook.

    Tip Ranks·
    US
    BNGO
    -1.73%
    Tip Ranks·
    US
    BNGO
    -1.73%

    Bionano Genomics Reports Strong Q3 Earnings Amid Challenges

    Bionano Genomics reported strong Q3 2025 earnings with $7.4 million in revenue, a 21% increase from Q3 2024. The company saw record flow cell sales, improved gross margins to 46%, and reduced operating expenses by 40%. Despite challenges in system installations and a slow Japanese market, Bionano's cash reserves remain solid at $31.8 million. The company reiterated its full-year revenue guidance of $26-$30 million and remains optimistic about future growth.

    Tip Ranks·
    US
    BNGO
    -1.73%
    Tip Ranks·
    US
    BNGO
    -1.73%

    Bionano Genomics | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 7.367 M

    LB filings·
    US
    BNGO
    -1.73%
    LB filings·
    US
    BNGO
    -1.73%

    Bionano Genomics Projects Q4 2025 Revenue of $7.5 to $7.9 Million

    Bionano Genomics Inc. projects Q4 2025 revenue between $7.5 and $7.9 million, following a 21% increase in Q3 revenue to $7.4 million. Growth was driven by a rise in consumables, software revenues, and nanochannel array flowcell sales. The company improved its gross margin to 46% and expects over 25 new OGM system installations in 2025, surpassing expectations.

    Reuters·
    US
    BNGO
    -1.73%
    Reuters·
    US
    BNGO
    -1.73%

    Bionano Genomics Q3 Revenue USD 7.4 Million

    Nov 13 (Reuters) - Bionano Genomics Q3 operating expenses USD 11.9 million. * Q3 adjusted operating expenses USD 9.7 million * Q3 gross margin 46% * outlook FY revenue USD 26-30 million

    Reuters·
    US
    BNGO
    -1.73%
    Reuters·
    US
    BNGO
    -1.73%
    © 2025 Longbridge｜Disclaimer